Expanded therapeutic use for melanoma antibody

The monoclonal antibody ipilimumab, indicated for the treatment of adults with advanced melanoma, is now licensed for first-line use


The monoclonal antibody ipilimumab (Yervoy), indicated for the treatment of adults with advanced (unresectable or metastatic) melanoma, is now licensed for first-line use.1

Ipilimumab enhances T-cell mediated responses by blocking the inhibitory signal of cytotoxic T-lymphocyte antigen-4 (CTLA-4). This results in T-cell activation, proliferation and lymphocyte infiltration into tumours, leading to tumour cell death.1

Analysis of pooled data for ipilimumab from phase II and III trials in chemotherapy-naive patients (n=78) showed estimated one- and two-year survival rates of 54.1% (95% CI 42.5-65.6) and 32% (95% CI 20.7-42.9), respectively.

In two retrospective observational studies in treatment-naive patients receiving ipilimumab (n=120 and n=61), estimated
one-year survival rates were 59.5% (95% CI 50.1-67.8) and 49.3% (95% CI 35.6-61.6).1

Reference

1. Yervoy Summary of Product Characteristics, December 2013.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more